KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.
On September27, 2017, KalVista Pharmaceuticals, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (“Annual Meeting”) and the following proposals were adopted:
| 1. | Election of two ClassII directors, Richard Aldrich and Edward W. Unkart, each to serve a three-year term, which will expire at the 2020 Annual Meeting of Stockholders or until such time as their respective successors have been duly elected and qualified: |
|
Nominees |
Shares For |
SharesWithheld |
Broker Non-Votes |
|
Richard Aldrich |
7,499,481 | 395,945 | |
|
Edward W. Unkart |
7,285,634 | 214,820 | 395,945 |
| 2. | Ratification of the appointment of Deloitte& Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending April30, 2018: |
|
Shares For |
SharesAgainst |
Shares Abstaining |
Broker Non-Votes |
|
7,880,132 |
4,848 | 11,419 |
About KALVISTA PHARMACEUTICALS, INC. (NASDAQ:KALV)
KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company’s HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
